Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice

Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis

“…6A–D) in contrast to the 50% decrease in plaque macrophages reported by Hara et al after 5 months of Xa inhibition. 37 However, despite our shorter 1-month time window of therapeutic intervention that may not have allowed for reduced plaque macrophage content, our observations of rapid downregulation of NF-kB in macrophage-rich regions and downstream inflammatory markers (TF, TAT complexes, sVCAM) (Fig. 4E–H), is consistent with the similar observations of Kadoglou et al in dabigatran-treated ApoE-null mice.…”

Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population‐Based Gutenberg Health Study

“…Furthermore, both valvular and arterial calcification have been reported in animals on warfarin treatment 17. By contrast, limited data from experimental animal studies have indicated a potentially beneficial effect of novel, direct‐acting anticoagulants on the development and progression of atherosclerosis 18, 19, 20…”

Treating the Unstable Atherosclerotic Plaque by Targeting Activated Factor X – Anticoagulation and Beyond –

“…During that study, Hara et al were able to show a resulting decrease in plaque burden and they also suggested a PARmediated effect. 10 The COMPASS trial will now evaluate whether rivaroxaban plays a role in secondary prevention of major cardiovascular events in patients with known coronary or peripheral artery disease. 11 A main limitation of studies using atherosclerosis models in mice is the comparison of merely plaque development in mice that have been fed a Western diet and unstable plaques in humans where exacerbation is causing ACS.…”